Patterns of hematologic malignancies and solid tumors among 37,838 first‐degree relatives of 13,896 patients with multiple myeloma in Sweden
Open accessThe DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Abstract
There are emerging data to suggest a role for genetic factors in the pathogenesis of multiple myeloma (MM). Based on small numbers, certain solid tumors have been reported to occur more frequently among blood relatives of patients with MM. Using population‐based data, we assessed risks for hematologic malignancies, monoclonal gammopathy of undetermined significance (MGUS), and solid tumors among first‐degree relatives of patients with MM. We included 13,896 patients with MM and 54,365 matched controls. Also we identified first‐degree relatives of patients with MM (n = 37,838) and controls (n = 151,068). Using a marginal survival model, we estimated relative risks (RRs) and 95% confidence intervals (CIs) for hematologic and solid tumors among family members of patients with MM and controls as measures of familial aggregation. Compared with relatives of controls, relatives of patients with MM had an increased risk of developing MM (RR = 2.1; 95% CI 1.6–2.9), MGUS (2.1; 1.5–3.1), acute lymphoblastic leukemia (ALL) (2.1; 1.0–4.2), any solid tumor (1.1; 1.0–1.1) and bladder cancer (1.3; 1.0–1.5). No significantly increased risk was found for other hematologic or solid malignancies. Our findings support a role for a shared susceptibility (genetic, environmental or both) that predisposes to MM, MGUS, ALL and bladder cancer. © 2009 UICC
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A Long-Term Study of Prognosis in Monoclonal Gammopathy of Undetermined Significance
Kyle, R. A., Therneau, T. M., Rajkumar, S. V., Offord, J. R., Larson, D. R., Plevak, M. F., & Melton, L. J. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa01133202 · Cited by 1,475 · cited 12×
“Compared to first-degree relatives of controls, we found that first-degree relatives of patients with MM had a 2-fold higher risk of developing MM.”
BackgroundInfluentialLandgren, O., Kyle, R. A., Pfeiffer, R. M., Katzmann, J. A., Caporaso, N. E., Hayes, R. B., Dispenzieri, A., Kumar, S., Clark, R. J., Baris, D., et al. (2009) · Blood · doi:10.1182/blood-2008-12-194241 · Cited by 1,127
Self-citation
Cited by
Variants in ELL2 influencing immunoglobulin levels associate with multiple myeloma
Swaminathan, B., Thorleifsson, G., Jöud, M., Ali, M., Johnsson, E., Ajore, R., Sulem, P., Halvarsson, B.-M., Eyjolfsson, G., Haraldsdottir, V., et al. (2015) · Nature Communications · doi:10.1038/ncomms8213 · Cited by 1,132
Self-citationRacial disparities in incidence and outcome in multiple myeloma: a population-based study
Waxman, A. J., Mink, P. J., Devesa, S. S., Anderson, W. F., Weiss, B. M., Kristinsson, S. Y., McGlynn, K. A., & Landgren, O. (2010) · Blood · doi:10.1182/blood-2010-07-298760 · Cited by 411
Self-citationSchinasi, L. H., Brown, E. E., Camp, N. J., Wang, S. S., Hofmann, J. N., Chiu, B. C., Miligi, L., Beane Freeman, L. E., de Sanjose, S., Bernstein, L., et al. (2016) · British Journal of Haematology · doi:10.1111/bjh.14199 · Cited by 57
Du, Z., Weinhold, N., Song, G. C., Rand, K. A., Van Den Berg, D. J., Hwang, A. E., Sheng, X., Hom, V., Ailawadhi, S., Nooka, A. K., et al. (2020) · Blood Advances · doi:10.1182/bloodadvances.2019000491 · Cited by 31
Thibaud, S., Subaran, R. L., Newman, S., Lagana, A., Melnekoff, D. T., Bodnar, S., Ram, M., Soens, Z., Genthe, W., Brander, T., et al. (2024) · Blood Cancer Discovery · doi:10.1158/2643-3230.bcd-23-0208 · Cited by 22
Metadata
- Authors
- Kristinsson, S. Y., Björkholm, M., Goldin, L. R., Blimark, C., Mellqvist, U., Wahlin, A., Turesson, I., & Landgren, O.
- Venue
- International Journal of Cancer
- Publisher
- Wiley
- Published
- 2009-07-06
- Volume
- 125
- Issue
- 9
- Pages
- 2147-2150
- ISSN
- 0020-7136 (ISSN-L)
- 1097-0215
- OpenAlex
- W2152701335
- Cited by
- 88
- References
- 2
- FWCI
- 4.36
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.